KRAZELVI
DEAD

Serial Number

97191230

Owner

Mirati Therapeutics, Inc.

Attorney

Eric R. Moran

Filing Date

Dec 27, 2021

Add to watchlist:

No watchlists yet
View on USPTO

KRAZELVI Trademark

Serial Number: 97191230

KRAZELVI is a trademark filed by Mirati Therapeutics, Inc. on December 27, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Mirati Therapeutics, Inc. (34 trademarks)

San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

December 27, 2021

Registration Date

Not Registered

Goods & Services

pharmaceuticals; pharmaceutical preparations; pharmaceutical products; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors

research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 3, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Mar 31, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 31, 2023 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 29, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 29, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 29, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 28, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 4, 2022 NWOS
NEW APPLICATION ENTERED
Dec 30, 2021 NWAP